Study Indicates A Superior Method For Inhibiting Tumor Cell Growth Using NEO 218

A Perillyl Alcohol-Conjugated Analog Of 3-Bromopyruvate Without Cellular Uptake Dependency On Monocarboxylate Transporter 1 And With Activity In 3-BP-Resistant Tumor Cells

Authors: Thomas C. Chen, MD, PhD¹, Jiali Yu¹. Eslam Nouri Nigjeh², WeijunWang¹, Phyo Thazin Myint³, Ebrahim Zandi³, Florence M. Hofman⁴and Axel H. Schönthal³

NeOnc Technologies conducted an in vitro study on MCT-1-positive HCT116 colon carcinoma cells to determine if cell growth inhibition could be increased using it conjugate NEO 218 formulation of 3-Bromopyruvate and its highly refined Peryllil Alchohol.

3-Bromopyruvate is a gold standard for tumor treatment because of its ability to inhibit energy production pathways of cancer cells without harming normal cells. However one of the issues with the drug is the ability for tumor cells to quickly develop a resistance to the compound. In this study, it was observed that NEO 218 was able to shut down enzymatic activity, severely lower cellular ATP content below life-sustaining levels, and trigger rapid cell death in the tumor without triggering an immediate resistance mechanism. 

¹ Department of Neurological Surgery, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA ² Department of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, ³ Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles,
CA 90089, US